A biobank has been created to investigate the prognostic value of biomarkers (mainly BNP) in patients implanted with durable mechanical assist devices comparing patients with advanced HF supported by MCS with those who are transplanted and those who remain on optimal medical therapy. Patients will be followed up for 25 years after inclusion.
All patients referred for advanced HF treatment at the Dept of Cardiology at Rigshospitalet.
Study Type
OBSERVATIONAL
Enrollment
1,000
Observation. No intervention (no collection of blood).
All patients evaluated for adv HF (HTX/LVAD) will be offered to contribute to this database; Blood samples will be collected from all at baseline. Patients receiving LVAD will contribute on a yearly basis (or until withdrawal of consent). For other patients no further blood will be collected unless they receive an LVAD at a later point.
Rigshospitalet
Copenhagen, DK, Denmark
RECRUITINGAlive
Time frame: 25 years from inclusion
Dead
Dead after inclusion in study
Time frame: 25 years from inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.